276 related articles for article (PubMed ID: 15652967)
1. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
[TBL] [Abstract][Full Text] [Related]
2. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.
Mayhew CN; Mampuru LJ; Chendil D; Ahmed MM; Phillips JD; Greenberg RN; Elford HL; Gallicchio VS
Antiviral Res; 2002 Nov; 56(2):167-81. PubMed ID: 12367722
[TBL] [Abstract][Full Text] [Related]
3. In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Sumpter LR; Inayat MS; Yost EE; Duvall W; Hagan E; Mayhew CN; Elford HL; Gallicchio VS
Antiviral Res; 2004 Jun; 62(3):111-20. PubMed ID: 15130534
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
[TBL] [Abstract][Full Text] [Related]
5. Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea.
Mayhew CN; Phillips JD; Cibull ML; Elford HL; Gallicchio VS
Antivir Chem Chemother; 2002 Sep; 13(5):305-14. PubMed ID: 12630679
[TBL] [Abstract][Full Text] [Related]
6. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Mayhew C; Oakley O; Piper J; Hughes NK; Phillips J; Birch NJ; Elford HL; Gallicchio VS
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1019-29. PubMed ID: 9449534
[TBL] [Abstract][Full Text] [Related]
7. Beyond hydroxyurea.
Smart T
GMHC Treat Issues; 1995 Sep; 9(9):5. PubMed ID: 11362909
[TBL] [Abstract][Full Text] [Related]
8. Use of hydroxyurea in heavily pretreated patients with HIV infection.
Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model.
Harvie P; Omar RF; Dusserre N; Lansac N; Désormeaux A; Gourde P; Simard M; Tremblay M; Beauchamp D; Bergeron MG
J Pharmacol Exp Ther; 1996 Nov; 279(2):1009-17. PubMed ID: 8930211
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Zala C; Salomón H; Cahn P
Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
[TBL] [Abstract][Full Text] [Related]
11. DNA-protective activity of new ribonucleotide reductase inhibitors.
Rauko P; Romanova D; Miadokova E; Macakova K; Novotny L; Elford HL; Szekeres T
Anticancer Res; 1997; 17(5A):3437-40. PubMed ID: 9413183
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
Leyden D; Ahmed N; Hassan HT
Anticancer Res; 2000; 20(1A):133-8. PubMed ID: 10769645
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Figul M; Söling A; Dong HJ; Chou TC; Rainov NG
Cancer Chemother Pharmacol; 2003 Jul; 52(1):41-6. PubMed ID: 12690517
[TBL] [Abstract][Full Text] [Related]
14. Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.
Fraternale A; Casabianca A; Orlandi C; Chiarantini L; Brandi G; Silvestri G; Magnani M
Virology; 2002 Oct; 302(2):354-62. PubMed ID: 12441079
[TBL] [Abstract][Full Text] [Related]
15. New data intensifies interest in hydroxyurea.
Santiago LG
GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Friend virus replication by a compound that reacts with the nucleocapsid zinc finger: anti-retroviral effect demonstrated in vivo.
Ott DE; Hewes SM; Alvord WG; Henderson LE; Arthur LO
Virology; 1998 Apr; 243(2):283-92. PubMed ID: 9568028
[TBL] [Abstract][Full Text] [Related]
17. Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model.
Chirigos MA; Ussery MA; Rankin JT; Herrmann D; Bicker U; Black PL
Immunopharmacol Immunotoxicol; 1990; 12(1):1-21. PubMed ID: 1693633
[No Abstract] [Full Text] [Related]
18. Hydroxyrea and ddI: French study published.
James JS
AIDS Treat News; 1995 Sep; (no 230):6. PubMed ID: 11362759
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
